^
Association details:
| Biomarker: | FOLR1 positive |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | CBP-1008 (Microtubule inhibitor, Folate receptor 1 inhibitor, TRPV6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase Ia/Ib study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors
Published date:
05/26/2022
Excerpt:
CBP-1008 was administered by intravenous infusion. Phase Ib clinical expansion study included 3 cohorts, platinum-resistant ovarian cancer (OC), metastatic triple negative breast cancer (TNBC) and other solid tumors. In 32 advanced platinum-resistant OC patients with FRα and/or TRPV6-positive expression, 6 PR and 16 SD were observed.
DOI:
10.1200/JCO.2022.40.16_suppl.3000
Trial ID:
